RPS6KA2
MOLECULAR TARGETribosomal protein S6 kinase A2
RPS6KA2 (ribosomal protein S6 kinase A2) is targeted by 31 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting RPS6KA2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | seliciclib | 4.91 | 135 |
| 2 | tofacitinib | 4.65 | 104 |
| 3 | alvocidib | 4.52 | 91 |
| 4 | foretinib | 4.34 | 76 |
| 5 | tozasertib | 4.33 | 75 |
| 6 | ruxolitinib | 4.23 | 68 |
| 7 | bosutinib | 4.08 | 58 |
| 8 | bi 2536 | 4.01 | 54 |
| 9 | midostaurin | 3.85 | 46 |
| 10 | brigatinib | 3.81 | 44 |
| 11 | neratinib | 3.66 | 38 |
| 12 | nintedanib | 3.61 | 36 |
| 13 | pelitinib | 3.50 | 32 |
| 14 | tae 684 | 3.43 | 30 |
| 15 | fedratinib | 3.40 | 29 |
| 16 | sp 600125 | 3.22 | 24 |
| 17 | bisindolylmaleimide ix | 3.14 | 22 |
| 18 | dovitinib | 3.09 | 21 |
| 19 | jnj 7706621 | 3.09 | 21 |
| 20 | at 9283 | 3.09 | 21 |
| 21 | lestaurtinib | 3.04 | 20 |
| 22 | pf 03758309 | 3.00 | 19 |
| 23 | ruboxistaurin | 2.94 | 18 |
| 24 | kw 2449 | 2.64 | 13 |
| 25 | ast 487 | 2.56 | 12 |
| 26 | gsk 461364 | 2.40 | 10 |
| 27 | su 014813 | 2.20 | 8 |
| 28 | enzastaurin | 2.08 | 7 |
| 29 | rg 547 | 2.08 | 7 |
| 30 | fisetin | 0.69 | 1 |
| 31 | sp600125 | 0.69 | 1 |
About RPS6KA2 as a Drug Target
RPS6KA2 (ribosomal protein S6 kinase A2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 31 compounds with documented RPS6KA2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
RPS6KA2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.